TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.
Stine Karlsen OversoeMichelle S ClementMichael H PedersenBritta WeberNiels Kristian AagaardGerda Elisabeth VilladsenHenning GrønbækStephen Jacques Hamilton-DutoitBoe Sandahl SørensenJens KelsenPublished in: Scandinavian journal of gastroenterology (2020)
The plasma TERT mutation was detected in 44% of HCC patients and in none of non-HCC cirrhotic patients; and was associated with increased mortality. We propose the TERT C228T mutation in ctDNA as a promising HCC biomarker for prognosis.